# Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma

> **NCT00782756** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Brain Cancer
- Malignant Glioma

## Interventions

- **OTHER:** radiotherapy (RT) in combination with temozolomide and bevacizumab

## Key facts

- **NCT ID:** NCT00782756
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-28
- **Primary completion:** 2017-03-23
- **Final completion:** 2017-03-23
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782756, "Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00782756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*